Array for stroke and neurological disorders research

Neurological disorders can affect the central, somatic and autonomic nervous system. At the molecular level, many analytes have been found to be involved in the pathophysiology of this complex interacting system.

Proteins such as neuron specific enolase (NSE) are considered to be neurochemical markers of brain damage due to stroke or head injury and also appear to have predictive value for outcome after acute stroke. BDNF and GFAP among others have also been linked to Alzheimer's disease and MS. Inflammatory processes have increasingly been shown to be implicated in the pathogenesis of cerebrovascular disease, and CRP has been identified as a predictor of future stroke risk.

The cerebral arrays have been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer's disease, MS and cerebrovascular disease. The cerebral arrays can be run on the Evidence analyser for high throughput or on the Evidence Investigator for for lower throughput.

List of analyte for Cerebral array I

Brain derived neurotrophic factor (BDNF)
Heart type fatty acid binding protein (h-FABP)
Glial Fibrillary acidic protein (GFAP)
Interleukin-6 (IL-6)

List of analyte for Cerebral array II

Neuron Specific Enolase (NSE)
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Soluble Tumour Necrosis Factor Receptor I (sTNFRI)
D-dimer
Thrombomodulin (TM)
High sensitivity C-reactive protein (hs CRP)